HUTCHMED (China) (HCM) Total Non-Current Liabilities (2015 - 2025)

HUTCHMED (China)'s (HCM) quarterly Total Non-Current Liabilities came in at $51.3 million in Q4 2025, down 16.87% year-on-year from $61.7 million in Q4 2024, and down 88.36% on a QoQ basis from $441.0 million in Q2 2025.

HUTCHMED (China) (HCM) Total Non-Current Liabilities (2015 - 2025) Analysis & Trends

HUTCHMED (China) (HCM) has 11 years of Total Non-Current Liabilities data on file, last reported at $51.3 million in Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 16.87% year-over-year to $51.3 million in Q4 2025; TTM through Dec 2025 was $51.3 million, a 16.87% decrease from a year earlier, with the FY2025 full-year figure at $5.0 million, up 28.69% from the prior year.
  • Total Non-Current Liabilities for Q4 2025 stood at $51.3 million, down from $441.0 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for HCM reached as high as $489.5 million in Q2 2024 and fell as low as -$2.8 billion in Q4 2023.
  • Historically, Total Non-Current Liabilities has averaged -$39.8 million across 5 years, with a median of $221.9 million in 2021.
  • Across the five-year window, Total Non-Current Liabilities surged 774.28% in 2021 and slumped 6148.6% in 2023, its largest moves.
  • Year by year, Total Non-Current Liabilities stood at $35.8 million in 2021, then surged by 31.16% to $47.0 million in 2022, then tumbled by 6148.6% to -$2.8 billion in 2023, then surged by 102.17% to $61.7 million in 2024, then fell by 16.87% to $51.3 million in 2025.
  • Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $51.3 million in Q4 2025, $441.0 million in Q2 2025, and $61.7 million in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 14.92 Bn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 18.28 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 11.64 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 33.47 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 599.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 20.09 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 1.24 Bn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 6.26 Bn
10 HUTCHMED (China) 241.90 Mn 243.61 Mn - 51.32 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 51.32 Mn
Jun 30, 2025 440.98 Mn
Dec 31, 2024 61.74 Mn
Jun 30, 2024 489.55 Mn
Dec 31, 2023 -2.84 Bn
Jun 30, 2023 478.19 Mn
Dec 31, 2022 46.96 Mn
Jun 30, 2022 322.27 Mn
Dec 31, 2021 35.81 Mn
Jun 30, 2021 253.67 Mn
Mar 31, 2021 221.92 Mn
Dec 31, 2020 16.03 Mn
Jun 30, 2020 -37.62 Mn
Dec 31, 2019 6.07 Mn
Sep 30, 2019 108.85 Mn
Jun 30, 2019 114.32 Mn
Mar 31, 2019 130.61 Mn
Dec 31, 2018 117.46 Mn
Jun 30, 2018 117.25 Mn
Dec 31, 2017 -18.75 Mn